EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Utility of Low-Dose Duvelisib for Advanced Mycosis Fungoides: A Single-Institution Study

Christopher Bazewicz, Nicolena Verardi, Oleg Akilov iD

The Oncologist · 2024

DOI: 10.1093/oncolo/oyad345 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2024. Verfasst von Christopher Bazewicz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Penn State University, Hershey, PA, USA. Hauptthemen laut MEDLINE: Mycosis Fungoides, Skin Neoplasms, Purines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Duvelisib, a small-molecule phosphatidylinositol 3-kinase-δ,γ inhibitor, has shown efficacy for mycosis fungoides (MF) at dosage ranges of 25-100 mg twice daily (BID), but with significant toxicity. We conducted a retrospective cohort study of patients with advanced MF treated with low-dose duvelisib (15 mg every other day to BID), in an effort to minimize toxicity. A total of 7 patients were included. The overall response rate on duvelisib was 71%, with the remaining patients maintaining stable disease. Mean modified Severity Weighted Assessment Tool score improved by 57.4% and mean percent body surface area involved improved by 52%. Median progression-free survival was 10.3 months. Adverse events occurred in 4 of 7 patients, the most common being fatigue (2/7; grades 1-2), nausea (2/7; grades 1-2), and transaminitis (2/7; grade 3). Overall, low-dose duvelisib showed efficacy for advanced MF with less toxicity, providing a rationale for its use as monotherapy and potentially combinatorial therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycosis FungoidesSkin NeoplasmsPurinesHumansRetrospective StudiesIsoquinolines

Stichwörter der Autor:innen

PI3K-δ,γ inhibitorcutaneous T-cell lymphomaduvelisibmycosis fungoides

Substanzen

duvelisibIsoquinolinesPurines

Autor:innen und Institutionen

  • Department of Dermatology, Penn State University, Hershey, PA, USA.
  • Cutaneous Lymphoma Program, University of Pittsburgh, Pittsburgh, PA, USA.

ORCID-Profile: Oleg Akilov

Zitieren

APA

Bazewicz, C., Verardi, N., & Akilov, O. (2024). Utility of Low-Dose Duvelisib for Advanced Mycosis Fungoides: A Single-Institution Study. The Oncologist. https://doi.org/10.1093/oncolo/oyad345

Vancouver

Bazewicz C, Verardi N, Akilov O. Utility of Low-Dose Duvelisib for Advanced Mycosis Fungoides: A Single-Institution Study. The Oncologist. 2024. doi:10.1093/oncolo/oyad345

BibTeX
@article{Bazewicz2024,
  author = {Bazewicz, Christopher and Verardi, Nicolena and Akilov, Oleg},
  title = {Utility of Low-Dose Duvelisib for Advanced Mycosis Fungoides: A Single-Institution Study},
  journal = {The Oncologist},
  year = {2024},
  doi = {10.1093/oncolo/oyad345}
}
Kostenlos starten →